Healthcare diagnostics company Labcorp Holdings (NYSE: LH) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.8% year on year to $3.54 billion. The company expects the full year’s revenue to be around $14.73 billion, close to analysts’ estimates. Its non-GAAP profit of $4.25 per share was 3.3% above analysts’ consensus estimates.
Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).
Labcorp (LH) Q1 CY2026 Highlights:
- Revenue: $3.54 billion vs analyst estimates of $3.51 billion (5.8% year-on-year growth, 0.9% beat)
- Adjusted EPS: $4.25 vs analyst estimates of $4.12 (3.3% beat)
- Adjusted EBITDA: $601.9 million vs analyst estimates of $604.5 million (17% margin, in line)
- The company slightly lifted its revenue guidance for the full year to $14.73 billion at the midpoint from $14.7 billion
- Management slightly raised its full-year Adjusted EPS guidance to $18.03 at the midpoint
- Operating Margin: 10.8%, up from 9.7% in the same quarter last year
- Organic Revenue rose 3.1% year on year (miss)
- Market Capitalization: $21.11 billion
StockStory’s Take
Labcorp’s first quarter was marked by continued growth in both its Diagnostics and Biopharma Laboratory Services businesses, supported by strategic partnerships and acquisitions. Management credited the quarter’s results to volume gains in specialty testing areas such as neurology and oncology, as well as successful integration of acquired laboratory assets. CEO Adam Schechter highlighted the company’s nationwide collaboration with the Children’s Hospital of Philadelphia and new test launches, particularly in Alzheimer’s and liquid biopsy diagnostics, as notable contributors. The impact of adverse weather was called out as a modest headwind to organic volume growth, though it did not materially alter the quarter’s overall performance.
Looking forward, Labcorp’s updated guidance is shaped by expectations for continued organic growth in Diagnostics, further margin improvement, and ongoing investments in technology and specialty testing. Management underscored their intention to expand digital health offerings, such as the MyLabcorp mobile app with AI features, and to advance operational efficiency through automation and robotics. CFO Julia Wang stated that the company will focus on disciplined capital deployment to support acquisitions, shareholder returns, and strategic facility investments, while monitoring policy changes and industry headwinds such as reimbursement shifts and regulatory initiatives.
Key Insights from Management’s Remarks
Management highlighted that specialty testing momentum, active M&A activity, and advances in automation and consumer health engagement were pivotal to first quarter performance.
- Specialty testing momentum: Labcorp reported double-digit growth in neurology and oncology testing, with Alzheimer’s diagnostics and liquid biopsy tests showing particularly strong adoption. Management noted that providers consolidating specialty testing with Labcorp also drove increased share of general diagnostics.
- Strategic partnerships and acquisitions: The acquisition of select assets from Crouse Health’s Laboratory Alliance and a new partnership with the Children’s Hospital of Philadelphia expanded Labcorp’s reach in both pediatric and regional diagnostic markets, enhancing its provider and patient network.
- Consumer health expansion: Labcorp OnDemand continued to grow at a double-digit pace, fueled by new launches in insulin resistance and customizable health panels, with the upcoming MyLabcorp app set to further engage consumers and improve access to clinical guidance.
- Technology and AI integration: The company expanded its AI-driven initiatives through collaborations with PathAI and Optum.ai, deploying digital pathology and operational efficiency tools to improve turnaround times and consistency, while a new partnership with AWS and Datavant aims to accelerate Alzheimer’s research.
- Operational efficiency through LaunchPad: Labcorp’s LaunchPad program continued to drive cost savings and margin expansion by leveraging technology, robotics, and process optimization, with margin improvements seen across both Diagnostics and Biopharma Laboratory Services segments.
Drivers of Future Performance
Labcorp’s outlook for the year centers on organic Diagnostics growth, margin expansion, and increased technology deployment, while keeping watch on reimbursement and regulatory risks.
- Diagnostics organic growth focus: Management expects the majority of revenue gains in Diagnostics to come from organic initiatives, particularly from specialty areas like oncology and neurology, as well as continued expansion of hospital partnerships and consumer health offerings.
- Margin expansion and efficiencies: The company anticipates further margin improvements, especially in Biopharma Laboratory Services, driven by operational efficiencies from LaunchPad and automation, with higher profitability expected in Central Labs relative to Early Development.
- Policy and regulatory headwinds: Management highlighted potential impacts from the CRUSH initiative, PAMA reporting, and ACA exchange dynamics, noting that changes in reimbursement or reporting participation could affect volumes and pricing, but also present partnership opportunities as hospital labs face financial pressure.
Catalysts in Upcoming Quarters
Looking ahead, our team will monitor (1) the adoption and engagement metrics for the MyLabcorp app and other digital health initiatives, (2) the trajectory of specialty testing growth, especially in Alzheimer’s and oncology, and (3) the pace and financial impact of newly announced hospital partnerships and acquisitions. Progress in automation and regulatory developments, such as PAMA reporting outcomes, will also be important to track.
Labcorp currently trades at $256.75, in line with $257.14 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
